If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
284
results.
Updated on
01/09/2026 [06:53:00]
Results 75 to 100 of 284
Absstract of: WO2026178144A1
The present invention relates to methods of preparing lipid nanoparticle compositions that include a polypeptide, a cation, compound capable of coordinating cations, and a population of encapsulating lipids. The methods afford lipid nanoparticles after a single operation and have favorable properties for the delivery of therapeutic agents.
Absstract of: WO2026178134A1
The present invention relates to methods of preparing lipid nanoparticle compositions that include a polypeptide, a cation, compound capable of coordinating cations, and a population of encapsulating lipids. The methods afford lipid nanoparticles after a single operation and have favorable properties for the delivery of therapeutic agents.
Absstract of: US20260250349A1
0000 The present disclosure provides compositions, methods of making, and use of a circular ribonucleic acid (circRNA) therapeutic for targeted delivery to immune cells, including T cells, for effector functions such as B cell depletion, providing, among other things, methods of treating B cell-mediated diseases such as autoimmune disease and cancer, meeting the medical need for efficacious and safe therapies that overcome the disadvantages of ex vivo CAR T therapy. Provided by the present disclosure is a circRNA therapeutic comprising: (i) a circRNA comprising a ribosome recruiting element, and a coding sequence encoding a CAR comprising, for example, an anti-CD19 antibody or antigen-binding fragment thereof, and (ii) a targeting moiety (e.g., anti-CD5) that binds to an immune cell (e.g., a T cell), wherein the circRNA is in a delivery vehicle, and a targeting moiety that binds to a T cell is conjugated to the delivery vehicle (e.g., a lipid nanoparticle).
Absstract of: WO2026177640A1
An absorbable bio-network for preventing fibrous adhesions following surgical or traumatic injury to the hand is disclosed. The bio-network comprises a polymer mixture of poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL) in a ratio of 60-80 wt% PLGA to 20-40 wt% PCL, and includes an inner drug reservoir formed of PLGA microspheres having a diameter of 20-50 μm and loaded with dexamethasone base at 1-5 wt%. The network is produced by electrospinning to obtain a membrane of 100-200 μm thickness, followed by application of a surface coating of hyaluronic acid and chitosan crosslinked with genipin. The construct provides a controlled drug-release profile characterized by a low initial release during the first two weeks and an increasing release thereafter over a period of 6-8 weeks. The system reduces adhesion formation without impairing early wound healing, and encompasses variations in polymer ratios, microsphere preparation, and coating conditions.
Absstract of: WO2026176363A1
Disclosed is a composition, method of manufacture, and method of therapeutic treatment that delivers a therapeutic amount of an active ingredient that induces a psychedelic effect in a human or mammal patient in a lipid nanoparticle emulsion. Preferably, this emulsion is delivered in controlled doses with a nasal spray matrix as a carrier.
Absstract of: WO2026178016A1
A lipid nanoparticle (LNP) comprising a plurality of lipids and a glycolipid adjuvant integrated into a core of the LNP. The LNPs may further comprise a nucleic acid encoding an antigen, including mRNA. A method of producing the LNPs is provided, including introducing the glycolipid adjuvant into a lipid phase prior to in-line mixing with an aqueous nucleic acid phase to form glycolipid-integrated LNPs with high incorporation efficiency and preserved physicochemical properties. Also disclosed are pharmaceutical compositions comprising the LNPs and methods of use, including immunizing a subject to induce tissue-specific cellular immunity. In certain embodiments, administration of the glycolipid-integrated LNPs induces liver-resident immune responses and provides sterile protection against parasitic infection.
Absstract of: WO2026174348A1
The present invention is directed to lipid nanoparticles, compositions, formulations and systems containing lipid-based nanoparticles and methods of treating diseases or conditions with said lipid nanoparticles, compositions, formulations and systems thereof. The present disclosure provides a lipid nanoparticle comprising (a) a nucleic acid comprising a nucleotide sequence encoding an N-terminal portion of a polypeptide of interest and a nucleotide sequence encoding an N-terminal intein, and (b) a targeting molecule displayed on the outer surface of the lipid nanoparticle. The present disclosure provides a lipid nanoparticle comprising (a) a nucleic acid comprising a nucleotide sequence encoding a C-terminal portion of a polypeptide of interest and encoding a C-terminal intein, and (b) a targeting molecule displayed on the outer surface of the lipid nanoparticle.
Absstract of: WO2026178449A1
The present disclosure relates to nanostructures capable of regulating intracellular immunomodulatory signaling and methods of using the nanostructures.
Absstract of: WO2026174972A1
A lipid nanoparticle, and a preparation method therefor and the use thereof. The lipid nanoparticle comprises packaging materials, namely, cationic lipids, neutral lipids, PEG or PEGylated lipids, and cholesterol or derivatives thereof at a molar percentage of (33-50)%:(10-13.33)%:(1.5-2)%:(38.5-51.33)%. The synthesis of a targeted LNP within the molar percentage range has a higher encapsulation efficiency, and can significantly improve the transduction efficiency of the targeted LNP, which can not only improve the encapsulation efficiency and loading capacity of the particle, but also enhances the targeting function of T cells, thereby realizing highly efficient transfection of T cells.
Absstract of: US20260248915A1
A near-infrared emissive aggregation-induced emission organic photothermal molecule and a preparation method thereof and an application are provided. The structure is shown in formula I:where R1, R2, R3, R4, R5, R6 are independently selected from groups containing alkyl chains. A preparation method of the organic photothermal molecule and an application thereof in preparing near-infrared aggregation-induced emission multifunctional protein nanoparticles are further provided.
Absstract of: WO2025043179A1
In some aspects, the present disclosure provides methods for generating CAR T cells in situ. The present disclosure provides lipid nanoparticles that selectively target a spleen cell, in particular, a lymphocyte such as a T cell. The lipid nanoparticle provided herein contain a five component composition that includes a permanently anionic lipid giving the lipid nanoparticle an apparent pKa of less than 6.
Absstract of: US20260248824A1
0000 Provided are lipid nanoparticles showing excellent drug migration to the pancreas. 0000 The lipid nanoparticles according to the present invention are lipid nanoparticles for delivering a drug to a target tissue, comprising: (a) a phosphatidylcholine-type phospholipid having an unsaturated fatty acid chain with 16 to 24 carbon atoms, and (b) a polyethylene glycol-modified lipid, wherein the target tissue is the pancreas.
Absstract of: US20260248969A1
0000 The disclosure relates to multimers of Glypican-3 (GPC3)-, CD44-, and Epithelial cell adhesion molecule (EpCAM)-specific peptides and the use thereof to detect and treat epithelial cell-derived cancers such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), breast cancer, colon cancer, gastric cancer, ovarian cancer, cervical cancer, and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients using the peptide multimers.
Absstract of: US20260248903A1
0000 Some aspects of the disclosure relate to vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses as well as methods of using the vaccines. Also described are combination vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses and other respiratory viruses (e.g., respiratory syncytial viruses and coronaviruses), as well as methods of using the vaccines.
Absstract of: WO2026177695A1
The invention relates to a method for the separation, purification, and industrial-scale production of exosomes from plant raw materials for use both as active and/or auxiliary substances in the food, cosmetic, and pharmaceutical industries and in scientific research conducted in the fields of molecular biology, biotechnology, food, agriculture, genetics, and medicine; and additionally for obtaining plant exosomes and purified and concentrated plant extracts while preserving their biological activity and without leaving chemical residues, characterized in that it comprises the process steps of: preparing the plant raw material by drying and grinding plant raw materials into powder form; performing filtration of the mixture of distilled water and plant raw material to remove coarse particles; performing low-speed centrifugation to allow the particles in the solution to settle and to achieve solid–liquid separation; cooling the mixture; performing a second filtration to remove remaining particles from the cooled and rested liquid; applying evaporation to remove excess water; performing ultrafiltration to remove impurity-forming particles; and performing homogenization to ensure uniform distribution of exosomes in the solution.
Absstract of: AU2026213995A1
Abstract The present invention relates to the mRNA vaccine of coronavirus spike protein with deletion of glycosites in the receptor binding domain (RBD), the subunit 1 (S1) domain, or the subunit 2 (S2) domain, or a combination thereof. The vaccine elicits broadly protective immune responses coronavirus and variants thereof. Abstract
Absstract of: US20260248723A1
A medical device for retrieval of kidney stone fragments from a urinary tract is provided. The medical device has a plurality of magnets arranged within a flexible sheath forming a flexible wire. The magnets are magnetically attached end-to-end and arranged with their magnetic polarities alternating in direction. The magnetization direction of each of the magnets is orthogonal to the length axis of the flexible wire. A removable inner stylet is situated within the flexible sheath allowing for modifiable flexibility of the wire. The medical device is dimensioned to be introduced into the urinary tract and standard endoscopic devices. The medical device is further dimensioned to allow for the wire with magnetically attached stone fragments to be retrieved from the urinary tract. The magnetic field along the length axis is sufficient to attract to the surface of the flexible wire superparamagnetic nanoparticles which have bound themselves to kidney stone fragments.
Absstract of: AU2026216794A1
PROTEIN-LOADED PLGA NANOSPHERES The present disclosure provides compositions comprising protein encapsulated nanoparticles, and methods of making said compositions. In an aspect, a composition may comprise a drug delivery vector and a therapeutic substance, wherein the composition elutes at least 1.0 pg of the therapeutic substance per 100,000 particles of the drug delivery vector over a period of time under conditions of a drug delivery vector release buffer, wherein the therapeutic substance, drug delivery vector and drug delivery vector release buffer comprise a solution, wherein the solution is centrifuged and a portion stored at about 1 to 10º C, and wherein the elution of the therapeutic substance is determined by ELISA assay. This disclosure further describes a method of controlling an immunophenotype in a patient suffering from a disease which impacts the immune system. PROTEIN-LOADED PLGA NANOSPHERES ug - u g
Absstract of: US20260248830A1
0000 The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.
Absstract of: US20260250331A1
The present disclosure relates to recombinant HIV Env polypeptides and their use in the treatment and prevention of HIV/AIDS.
Absstract of: US20260248736A1
The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic agents.
Absstract of: AU2026213981A1
Abstract Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed. Abstract
Absstract of: US20260248737A1
0000 The present disclosure is directed to core-shell nanoparticles, compositions comprising core-shell nanoparticles, and methods of their use.
Absstract of: US20260250334A1
The invention relates to a positively charged peptide capable of non-covalently interact with negatively charged extracellular vesicles or nanoparticles. Said peptide is a fragment of the bacterial protein P40 and shows better interaction capabilities that the entire bacterial protein P40. The peptide of the invention can also be linked to a targeting element, such as targeting peptide, DNA aptamer, RNA aptamer, a protein, an antibody or a fragment thereof that binds to a target molecule, therefore it can be used for the targeted delivery of extracellular vesicles or nanoparticles further comprising a bioactive agent to a target cell, tissue or particle like a virus, that comprise the target molecule. Therefore, the present invention also relates to a carrier complex comprising the peptide of the invention non covalently bound to an extracellular vesicle or nanoparticle comprising a bioactive agent and its uses.
Nº publicación: US20260248951A1 27/08/2026
Applicant:
ONCONQUER MEDICAL LTD [IL]
ONCONQUER MEDICAL LTD
Absstract of: US20260248951A1
Apparatus and methods are described for capturing circulating tumor cells (CTC) in vivo. An intravascular implantable implant body (20, 54, 84) is implanted in a blood vessel of a subject. Antibody-conjugated magnetic particles (80) are configured, upon being released into a bloodstream of the subject, to (a) magnetically attach to the implant body (20, 54, 84), and (b) selectively bind circulating tumor cells (CTC) in the blood vessel. A releasing element (82, 85) periodically releases antibody-conjugated magnetic particles (80) into the subject's bloodstream such as to replenish the implant body (20, 54, 84) with antibody-conjugated magnetic particles (80). Other applications are also described.
BOPI
Electronic site
